See more : NKGen Biotech, Inc. Common Stock (NKGN) Income Statement Analysis – Financial Results
Complete financial analysis of Coeptis Therapeutics Holdings, Inc. (COEPW) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Coeptis Therapeutics Holdings, Inc., a leading company in the Biotechnology industry within the Healthcare sector.
- URU Metals Limited (URU.L) Income Statement Analysis – Financial Results
- Parabellum Acquisition Corp. (PRBMW) Income Statement Analysis – Financial Results
- PARK24 Co., Ltd. (PKCOF) Income Statement Analysis – Financial Results
- Apoorva Leasing Finance and Investment Company Limited (APOORVA.BO) Income Statement Analysis – Financial Results
- Annehem Fastigheter AB (ANNE-B.ST) Income Statement Analysis – Financial Results
Coeptis Therapeutics Holdings, Inc. (COEPW)
About Coeptis Therapeutics Holdings, Inc.
Coeptis Therapeutics Holdings, Inc., a biopharmaceutical company, develops and commercializes generic and branded pharmaceutical products and cell therapy platforms for patients with cancer. Its product portfolio consists of CD38-GEAR-NK, a Vy-Gen drug product for the treatment of CD38-related cancers, including multiple myeloma, chronic lymphocytic leukemia, and acute myeloid leukemia; and CD38-Diagnostic, an in vitro screening tool to provide the ability to pre-determine which cancer patients are most likely to benefit from targeted anti-CD38 monoclonal antibodies therapies. The company has collaboration with Statera BioPharma to develop and commercialize STAT-201 for Crohn's disease; and Vici Health Sciences, LLC to co-develop and share ownership rights to CPT60621 for the treatment of Parkinson's Disease. Coeptis Therapeutics Holdings, Inc. was founded in 2017 and is headquartered in Wexford, Pennsylvania.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 |
|---|---|---|---|---|---|
| Revenue | 0.00 | 0.00 | 75.00K | 30.76K | 0.00 |
| Cost of Revenue | 1.00M | 1.00M | 447.41K | 964.22K | 0.00 |
| Gross Profit | -1.00M | -1.00M | -372.41K | -933.46K | 0.00 |
| Gross Profit Ratio | 0.00% | 0.00% | -496.55% | -3,034.54% | 0.00% |
| Research & Development | 6.67M | 20.89K | 0.00 | 3.54K | 0.00 |
| General & Administrative | 3.95M | 34.17M | 14.12M | 5.77M | 0.00 |
| Selling & Marketing | 12.71K | 8.33K | 2.92K | 6.61K | 0.00 |
| SG&A | 13.82M | 34.18M | 14.12M | 5.78M | 0.00 |
| Other Expenses | 0.00 | 233.70K | 785.79K | -2.29M | 0.00 |
| Operating Expenses | 20.49M | 34.20M | 14.12M | 5.78M | 0.00 |
| Cost & Expenses | 21.49M | 34.20M | 14.12M | 6.74M | 0.00 |
| Interest Income | 0.00 | 0.00 | 0.00 | 1.20K | 0.00 |
| Interest Expense | -107.69K | 218.41K | 187.13K | 148.19K | 0.00 |
| Depreciation & Amortization | 1.00M | 1.00M | 447.41K | 323.43K | 171.86K |
| EBITDA | -20.16M | -36.35M | -12.81M | -8.68M | 171.86K |
| EBITDA Ratio | 0.00% | 0.00% | -17,083.65% | -28,232.72% | 0.00% |
| Operating Income | -21.49M | -34.20M | -14.05M | -6.86M | 0.00 |
| Operating Income Ratio | 0.00% | 0.00% | -18,727.91% | -22,305.53% | 0.00% |
| Total Other Income/Expenses | 224.58K | -3.38M | 596.65K | -2.29M | -2.23K |
| Income Before Tax | -21.27M | -37.57M | -13.45M | -9.16M | -2.23K |
| Income Before Tax Ratio | 0.00% | 0.00% | -17,932.37% | -29,765.89% | 0.00% |
| Income Tax Expense | 0.00 | 3.39M | 972.92K | -2.15M | 0.00 |
| Net Income | -21.27M | -40.97M | -14.42M | -7.01M | -2.23K |
| Net Income Ratio | 0.00% | 0.00% | -19,229.60% | -22,787.28% | 0.00% |
| EPS | -0.83 | -2.87 | -1.32 | -0.75 | 0.00 |
| EPS Diluted | -0.83 | -2.87 | -1.32 | -0.75 | 0.00 |
| Weighted Avg Shares Out | 25.69M | 14.30M | 10.91M | 9.38M | 10.78M |
| Weighted Avg Shares Out (Dil) | 25.69M | 14.30M | 10.91M | 9.38M | 10.78M |
Source: https://incomestatements.info
Category: Stock Reports